Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:RLMD NASDAQ:SCPH NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$6.55+4.0%$5.58$3.79▼$14.60$345.84M-0.94787,461 shs908,250 shsRLMDRelmada Therapeutics$2.20+3.3%$1.29$0.24▼$3.98$70.70M0.91517,318 shs363,635 shsSCPHscPharmaceuticals$5.67$5.37$1.94▼$6.28$302.20M0.311.99 million shsN/ATKNOAlpha Teknova$5.05-4.9%$4.78$3.94▼$10.37$284.17M0.41376,033 shs654,048 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics+11.90%+13.72%+23.53%+2.44%+2.44%RLMDRelmada Therapeutics+7.04%-1.39%+33.13%+217.86%-38.97%SCPHscPharmaceuticals-1.37%+0.18%+1.61%+26.85%+42.82%TKNOAlpha Teknova+1.34%-16.64%+22.07%+2.31%+7.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$6.55+4.0%$5.58$3.79▼$14.60$345.84M-0.94787,461 shs908,250 shsRLMDRelmada Therapeutics$2.20+3.3%$1.29$0.24▼$3.98$70.70M0.91517,318 shs363,635 shsSCPHscPharmaceuticals$5.67$5.37$1.94▼$6.28$302.20M0.311.99 million shsN/ATKNOAlpha Teknova$5.05-4.9%$4.78$3.94▼$10.37$284.17M0.41376,033 shs654,048 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics+11.90%+13.72%+23.53%+2.44%+2.44%RLMDRelmada Therapeutics+7.04%-1.39%+33.13%+217.86%-38.97%SCPHscPharmaceuticals-1.37%+0.18%+1.61%+26.85%+42.82%TKNOAlpha Teknova+1.34%-16.64%+22.07%+2.31%+7.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 2.67Moderate Buy$20.00205.34% UpsideRLMDRelmada Therapeutics 1.75Reduce$1.00-54.55% DownsideSCPHscPharmaceuticals 1.75Reduce$7.7837.27% UpsideTKNOAlpha Teknova 2.67Moderate Buy$10.0098.02% UpsideCurrent Analyst Ratings BreakdownLatest RLMD, CADL, SCPH, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CADLCandel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RLMDRelmada TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SCPHscPharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TKNOAlpha TeknovaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.009/27/2025CADLCandel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RLMDRelmada TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SCPHscPharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TKNOAlpha TeknovaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.008/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.35(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,996.63N/AN/A$1.41 per share4.65RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASCPHscPharmaceuticals$49.97M6.05N/AN/A$0.27 per share21.00TKNOAlpha Teknova$37.74M7.16N/AN/A$1.55 per share3.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.42N/AN/AN/A-55.24%-26.51%-18.40%11/6/2025 (Estimated)Latest RLMD, CADL, SCPH, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025RLMDRelmada Therapeutics-$0.04N/AN/AN/AN/AN/A8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 million8/7/2025Q2 2025TKNOAlpha Teknova-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.017.047.04RLMDRelmada TherapeuticsN/A4.114.11SCPHscPharmaceuticalsN/A3.853.14TKNOAlpha Teknova0.175.874.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%RLMDRelmada Therapeutics45.24%SCPHscPharmaceuticals89.52%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%RLMDRelmada Therapeutics20.70%SCPHscPharmaceuticals4.78%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableTKNOAlpha Teknova24053.51 million46.83 millionNot OptionableRLMD, CADL, SCPH, and TKNO HeadlinesRecent News About These CompaniesAlpha Teknova (NASDAQ:TKNO) Given Sell (D-) Rating at Weiss RatingsOctober 8 at 4:44 PM | marketbeat.comDoes Alpha Teknova (TKNO) Have Meaningful Growth Opportunities?September 1, 2025 | insidermonkey.comAlpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comAlpha Teknova (TKNO) Q2 Revenue Jumps 7%August 8, 2025 | aol.comATeknova Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comTeknova to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comPleasing Signs As A Number Of Insiders Buy Alpha Teknova StockJuly 9, 2025 | finance.yahoo.comMartha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) StockJuly 2, 2025 | insidertrades.comAlpha Teknova, Inc. (TKNO) Income Statement - Yahoo FinanceJune 28, 2025 | ca.finance.yahoo.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comAlpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comTeknova Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAlpha Teknova (TKNO) Traded Lower on Increased UncertaintyApril 30, 2025 | msn.comAlpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comQTeknova to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAlpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation systemMarch 20, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | globenewswire.comTeknova, Pluristyx announce collaboration over next-generation cell therapiesMarch 11, 2025 | markets.businessinsider.comTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesMarch 11, 2025 | globenewswire.comEarnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67March 8, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLMD, CADL, SCPH, and TKNO Company DescriptionsCandel Therapeutics NASDAQ:CADL$6.55 +0.25 (+3.97%) Closing price 04:00 PM EasternExtended Trading$6.60 +0.04 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$2.20 +0.07 (+3.29%) Closing price 04:00 PM EasternExtended Trading$2.24 +0.03 (+1.59%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.scPharmaceuticals NASDAQ:SCPH$5.67 0.00 (0.00%) As of 10/7/2025scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Alpha Teknova NASDAQ:TKNO$5.05 -0.26 (-4.90%) Closing price 04:00 PM EasternExtended Trading$5.09 +0.04 (+0.79%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
